Novo Integrated Sciences Reports First Quarter Financial Results

Rhea-AI Summary

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) reported 47% revenue growth for the fiscal quarter ended November 30, 2021, reaching $3.16 million, attributed mainly to the Acenzia acquisition. Following a $15 million registered direct offering, the company aims to enhance its decentralized healthcare ecosystem. Anticipating 400% revenue growth and expanding internationally, Novo plans to launch NovoConnect by March 31, 2022. Despite an increase in operating costs and a net loss of $1.81 million, the company is confident about future integration benefits.

Positive

• 47% revenue growth year-over-year, reaching $3.16 million.
• Completed a registered direct offering, generating $15 million.
• Aiming for 400% revenue growth with upcoming product launches and acquisitions.
• Launch of NovoConnect mobile application expected by March 31, 2022.

Negative

• Net loss increased to $1.81 million, up 134.2% from the previous year.
• Operating costs rose 67.6% to $2.63 million due to acquisition-related expenses.

BELLEVUE, Wash.--(BUSINESS WIRE)-- Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation, today reported its financial results for the fiscal quarter ended November 30, 2021.

Robert Mattacchione, Novo’s CEO and Board Chairman, stated, “We are pleased with the 47% revenue growth year-over-year. Subsequent to the quarter, we strengthened our balance sheet with the completion of a registered direct offering, resulting in gross proceeds of $15 million to Novo, to support the continued strategic investment in our decentralized, multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation. We intend to launch NovoConnect by March 31, 2022. NovoConnect is a patient-first healthcare mobile application focused on providing a robust digital based offering of services and products, alongside a secure patient chart that empowers the patient to have direct control of their health and wellness. We look forward to closing our U.S. pharmacy acquisitions, further expanding our patient touch points and multiplying our annual gross revenue by an expected 400%. In addition, Novo anticipates expansion into international jurisdictions, beyond the U.S. and Canada during the current fiscal year, providing an extended broad physical base for our global virtual solutions.”

Financial Highlights:

• As of November 30, 2021, the Company’s cash and cash equivalents were $8.8 million, total assets were $63.9 million, total liabilities were $20.3 million, and stockholders’ equity was $43.7 million.
• Revenues for the three months ended November 30, 2021 were $3.16 million, representing an increase of $1 million, or 46.7%, from $2.16 million for the same period in 2020. The increase in revenue is principally due to the acquisition of Acenzia, Inc. in June 2021. Acenzia’s revenue for the three months ended November 30, 2021 was $981,852.
• Operating costs for the three months ended November 30, 2021 were $2,630,125, representing an increase of $1,060,951, or 67.6%, from $1,569,174 for the same period in 2020. The increase in operating costs is principally due to the temporary increase in overhead expenses associated with the acquisitions of Acenzia, PRO-DIP, and Terragenx which was approximately $808,000 for the three months ended November 30, 2021. In subsequent quarters, this temporary increase in overhead expenses associated with Acenzia, PRO-DIP, and Terragenx is projected to decrease significantly as the Company integrates and consolidates operations.
• Net loss attributed to Novo Integrated Sciences, Inc. for the three months ended November 30, 2021 was $1,806,587, representing an increase of $1,035,117, or 134.2%, from $771,470 for the same period in 2020. The increase in net loss is principally due (i) an increase in foreign currency transaction losses, and (ii) a temporary increase in overhead expenses associated with the acquisitions of Acenzia, PRO-DIP, and Terragenx which was approximately $808,000 for the three months ended November 30, 2021. In subsequent quarters, this temporary increase in overhead expenses associated with Acenzia, PRO-DIP, and Terragenx is projected to decrease significantly as the Company integrates and consolidates operations.
• Subsequent to the quarter end, the Company completed a registered direct offering with accredited institutional investors, resulting in gross proceeds of $15 million to Novo.

Operational Milestones:

• Acquired 91% of Terragenx and the intellectual property portfolio, in an all-share transaction priced at $3.35 per share, for the unique formulation and manufacturing capability to produce a water-soluble iodine micro-nutrient that is FDA and Health Canada approved for over-the-counter and e-commerce distribution.
• Established a 50/50 joint venture company, MiTelemed+, with EK-Tech Solutions Inc. to operate, support, and expand access and functionality of EK-Tech’s enhanced proprietary Telehealth platform (“iTelemed”). MiTelemed+, through the iTelemed platform, allows Novo to offer the patient and the practitioner a sophisticated and enhanced telehealth interaction. Through the interface of sophisticated peripheral based diagnostic tools operated by skilled support workers in the patient’s remote location, the practitioner’s ability and comfort to provide a uniquely comprehensive evaluation, diagnosis, and treatment solution is dramatically elevated.

About Novo Integrated Sciences, Inc.

Novo Integrated Sciences, Inc. is pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation. Novo offers an essential and differentiated solution to deliver, or intend to deliver, these services and products through the integration of medical technology, advanced therapeutics, and rehabilitative science.

We believe that “decentralizing” healthcare, through the integration of medical technology and interconnectivity, is an essential solution to the rapidly evolving fundamental transformation of how non-catastrophic healthcare is delivered, both now and in the future. Specific to non-critical care, ongoing advancements in both medical technology and inter-connectivity are allowing for a shift of the patient/practitioner relationship to the patient’s home and away from on-site visits to primary medical centers with mass-services. This acceleration of “ease-of-access” in the patient/practitioner interaction for non-critical care diagnosis and subsequent treatment minimizes the degradation of non-critical health conditions to critical conditions as well as allowing for more cost-effective healthcare distribution.

The Company’s decentralized healthcare business model is centered on three primary pillars to best support the transformation of non-catastrophic healthcare delivery to patients and consumers:

• First Pillar: Service Networks. Deliver multidisciplinary primary care services through (i) an affiliate network of clinic facilities, (ii) small and micro footprint sized clinic facilities primarily located within the footprint of box-store commercial enterprises, (iii) clinic facilities operated through a franchise relationship with the Company, and (iv) corporate operated clinic facilities.
• Second Pillar: Technology. Develop, deploy, and integrate sophisticated interconnected technology, interfacing the patient to the healthcare practitioner thus expanding the reach and availability of the Company’s services, beyond the traditional clinic location, to geographic areas not readily providing advanced, peripheral based healthcare services, including the patient’s home.
• Third Pillar: Products. Develop and distribute effective, personalized health and wellness product solutions allowing for the customization of patient preventative care remedies and ultimately a healthier population. The Company’s science-first approach to product innovation further emphasizes our mandate to create and provide over-the-counter preventative and maintenance care solutions.

Innovation through science combined with the integration of sophisticated, secure technology assures Novo Integrated Sciences of continued cutting-edge advancement in patient first platforms.

For more information concerning Novo Integrated Sciences, please visit www.novointegrated.com. For more information on Novo Healthnet Limited, Novo’s wholly owned subsidiary, please visit www.novohealthnet.com.

Twitter, LinkedIn, Facebook, Instagram, YouTube

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts included in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by words such as "believe," “intend,” "expect," "anticipate," "plan," "potential," "continue" or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks and uncertainties are discussed in Novo’s filings with the Securities and Exchange Commission. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond Novo’s control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects Novo’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Novo assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The contents of any website referenced in this press release are not incorporated by reference herein.

NOVO INTEGRATED SCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS As of November 30, 2021 (unaudited) and August 31, 2021
		November 30,				August 31,
		2021				2021
		(unaudited)
ASSETS
Current Assets:
Cash and cash equivalents		$	8,800,754			$	8,293,162
Accounts receivable, net			1,696,211				1,468,429
Inventory			364,147				339,385
Other receivables, current portion			1,118,264				814,157
Prepaid expenses and other current assets			263,199				218,376
Total current assets			12,242,575				11,133,509
Property and equipment, net			6,096,534				6,070,291
Intangible assets, net			33,821,915				32,436,468
Right-of-use assets, net			2,446,736				2,543,396
Other receivables, net of current portion			370,833				692,738
Goodwill			8,955,694				9,081,879
TOTAL ASSETS		$	63,934,287			$	61,958,281
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts payable		$	1,314,939			$	1,449,784
Accrued expenses			1,376,848				1,129,309
Accrued interest (principally to related parties)			370,488				366,280
Government loans and notes payable, current portion			9,674,981				4,485,649
Convertible notes payable, net of discount of $702,984			1,172,016				-
Contingent liability			741,083				-
Due to related parties			469,199				478,920
Finance lease liability, current portion			18,921				23,184
Operating lease liability, current portion			514,568				530,797
Total current liabilities			15,653,043				8,463,923
Debentures, related parties			968,558				982,205
Notes payable, net of current portion			172,698				5,133,604
Finance lease liability, net of current portion			12,982				16,217
Operating lease liability, net of current portion			1,979,239				2,057,805
Deferred tax liability			1,479,525				1,500,372
TOTAL LIABILITIES			20,266,045				18,154,126
Commitments and contingencies			-				-
STOCKHOLDERS’ EQUITY
Novo Integrated Sciences, Inc.
Convertible preferred stock; $0.001 par value; 1,000,000 shares authorized; 0 and 0 shares issued and outstanding at November 30, 2021 and August 31, 2021, respectively			-				-
Common stock; $0.001 par value; 499,000,000 shares authorized; 28,645,144 and 26,610,144 shares issued and outstanding at November 30, 2021 and August 31, 2021, respectively			28,645				26,610
Additional paid-in capital			55,092,070				54,579,396
Common stock to be issued (4,359,841 and 3,622,199 shares at November 30, 2021 and August 31, 2021)			10,409,457				9,236,607
Other comprehensive income			887,544				991,077
Accumulated deficit			(22,775,861	)			(20,969,274	)
Total Novo Integrated Sciences, Inc. stockholders’ equity			43,641,855				43,864,416
Noncontrolling interest			26,387				(60,261	)
Total stockholders’ equity			43,668,242				43,804,155
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY		$	63,934,287			$	61,958,281

NOVO INTEGRATED SCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS For the Three Months Ended November 30, 2021 and 2020 (unaudited)
		Three Months Ended
		November 30,				November 30,
		2021				2020
		(unaudited)				(unaudited)
Revenues		$	3,161,927			$	2,155,506
Cost of revenues			1,895,461				1,344,056
Gross profit			1,266,466				811,450
Operating expenses:
Selling expenses			168				1,243
General and administrative expenses			2,629,957				1,567,931
Total operating expenses			2,630,125				1,569,174
Loss from operations			(1,363,659	)			(757,724	)
Non operating income (expense)
Interest income			8,388				8,562
Interest expense			(68,730	)			(23,941	)
Amortization of debt discount			(57,840	)			-
Foreign currency transaction losses			(334,554	)			-
Total other income (expense)			(452,736	)			(15,379	)
Loss before income taxes			(1,816,395	)			(773,103	)
Income tax expense			-				-
Net loss		$	(1,816,395	)		$	(773,103	)
Net loss attributed to noncontrolling interest			(9,808	)			(1,633	)
Net loss attributed to Novo Integrated Sciences, Inc.		$	(1,806,587	)		$	(771,470	)
Comprehensive loss:
Net loss			(1,816,395	)			(773,103	)
Foreign currency translation (loss) gain			(103,533	)			10,596
Comprehensive loss:		$	(1,919,928	)		$	(762,507	)
Weighted average common shares outstanding - basic and diluted			26,924,705				23,508,353
Net loss per common share - basic and diluted		$	(0.07	)		$	(0.03	)

NOVO INTEGRATED SCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY For the Three Months Ended November 30, 2021 and 2020 (unaudited)
																										Total
										Additional				Common				Other								Novo
		Common Stock								Paid-in				Stock To				Comprehensive				Accumulated				Stockholders’				Noncontrolling				Total
		Shares				Amount				Capital				Be Issued				Income				Deficit				Equity				Interest				Equity
Balance, August 31, 2021			26,610,144			$	26,610			$	54,579,396			$	9,236,607			$	991,077			$	(20,969,274	)		$	43,864,416			$	(60,261	)		$	43,804,155
Common stock for services			35,000				35				64,715				-				-				-				64,750				-				64,750
Common stock issued as collateral and held in escrow			2,000,000				2,000				(2,000	)			-				-				-				-				-				-
Common stock to be issued for purchase of Terragenx			-				-				-				983,925				-				-				983,925				97,311				1,081,236
Common stock to be issued for purchase of Mullin assets			-				-				-				188,925				-				-				188,925				-				188,925
Value of warrants issued with convertible notes			-				-				295,824				-				-				-				295,824				-				295,824
Fair value of stock options			-				-				154,135				-				-				-				154,135				-				154,135
Foreign currency translation loss			-				-				-				-				(103,533	)			-				(103,533	)			(855	)			(104,388	)
Net loss			-				-				-				-				-				(1,806,587	)			(1,806,587	)			(9,808	)			(1,816,395	)
Balance, November 30, 2021			28,645,144			$	28,645			$	55,092,070			$	10,409,457			$	887,544			$	(22,775,861	)		$	43,641,855			$	26,387			$	43,668,242
Balance, August 31, 2020			23,466,236			$	23,466			$	44,905,454			$	-			$	1,199,696			$	(16,507,127	)		$	29,621,489			$	(49,859	)		$	29,571,630
Common stock issued for cash			21,905				22				91,978				-				-				-				92,000				-				92,000
Common stock issued for services			65,000				65				247,935				-				-				-				248,000				-				248,000
Foreign currency translation gain			-				-				-				-				10,596				-				10,596				(225	)			10,371
Net loss			-				-				-				-				-				(771,470	)			(771,470	)			(1,633	)			(773,103	)
Balance, November 30, 2020			23,553,141			$	23,553			$	45,245,367			$	-			$	1,210,292			$	(17,278,597	)		$	29,200,615			$	(51,717	)		$	29,148,898

NOVO INTEGRATED SCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS For the Three Months Ended November 30, 2021 and 2020 (unaudited)
		Three Months Ended
		November 30,				November 30,
		2021				2020
		(unaudited)				(unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss		$	(1,816,395	)		$	(773,103	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization			694,282				357,924
Fair value of vested stock options			154,135				-
Common stock issued for services			64,750				248,000
Operating lease expense			163,879				149,379
Amortization of debt discount			57,840				-
Foreign currency transaction losses			334,554				-
Changes in operating assets and liabilities:
Accounts receivable			(253,079	)			274,577
Inventory			12,245				-
Prepaid expenses and other current assets			(47,335	)			(300,743	)
Accounts payable			(55,056	)			8,552
Accrued expenses			82,933				31,067
Accrued interest			9,481				2,858
Operating lease liability			(161,337	)			(146,614	)
Net cash used in operating activities			(759,103	)			(148,103	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment			(120,397	)			-
Cash acquired with acquisition			29,291				-
Net cash used in investing activities			(91,106	)			-
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayments to related parties			(3,127	)			(48,389	)
Repayments of finance leases			(7,088	)			-
Proceeds from the sale of common stock, net of offering costs			-				92,000
Proceeds from issuance of convertible notes, net			1,410,000				-
Net cash provided by financing activities			1,399,785				43,611
Effect of exchange rate changes on cash and cash equivalents			(41,984	)			7,165
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS			507,592				(97,327	)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD			8,293,162				2,067,718
CASH AND CASH EQUIVALENTS, END OF PERIOD		$	8,800,754			$	1,970,391
CASH PAID FOR:
Interest		$	64,522			$	19,642
Income taxes		$	-			$	-
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES:
Common stock to be issued for intangible assets		$	188,925			$	-
Common stock to be issued for acquisition		$	983,925			$	-

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20220118006135/en/

Chris David, COO-President

Novo Integrated Sciences, Inc.

chris.david@novointegrated.com

(888) 512-1195

Source: Novo Integrated Sciences, Inc.

FAQ

What are Novo Integrated Sciences' recent financial results for NVOS?

Novo reported a 47% revenue growth for the quarter ending November 30, 2021, with revenues reaching $3.16 million.

How much did Novo Integrated Sciences raise in its recent offering?

Novo completed a registered direct offering, raising $15 million to strengthen its balance sheet.

What is the expected revenue growth for Novo Integrated Sciences?

Novo anticipates multiplying its annual gross revenue by an expected 400% through strategic initiatives.

What is NovoConnect and when is it launching?

NovoConnect is a patient-first healthcare mobile application set to launch by March 31, 2022.